Bristol Myers Squibb Non-GAAP EPS of $1.83 Beats by $0.03, Revenue of $12B in-line

Seeking Alpha2022-02-04
  • Bristol Myers Squibbpress release(NYSE:BMY): Q4 Non-GAAP EPS of $1.83beats by $0.03.
  • Revenue of $12B (+8.1% Y/Y) in-line.
  • Revenue breakdown:Eliquis of $2.67B vs. $2.41B in 3Q21; Opdivo of $1.99B vs. $1.91B in 3Q21; Revlimid of $3.33B vs. $3.35B in 3Q21.
  • Announces $15 Billion Share Repurchase Authorization; $5 Billion Accelerated Share Repurchase Agreement to be Executed During the First Quarter 2022
  • Bristol Myers Squibb is introducing its 2022 GAAP EPS guidance range of $3.37 - $3.67 and reaffirming its non-GAAP EPS guidance range of $7.65 - $7.95
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

Leave a comment
5